Press Releases
Debiopharm to showcase research results of their DDR Inhibitors at the 2024 AACR Conference in San Diego
Debiopharm Launches Expansion of WEE1 Inhibitor Monotherapy Research in Gynecological Cancers and Other Biomarker-Driven Solid Tumors
Debiopharm and Repare Therapeutics Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer
Debiopharm Shares Oncology Program Updates at ASCO 2023 for Novel WEE1 Inhibitor, and First-In-Class CA IX Theranostic Approach
Debiopharm Launches Phase 1 Research in Small Cell Lung Cancer with WEE1 inhibitor Debio 0123 to Outsmart DDR
Debiopharm Launches Phase 1/2 Combination Trial Investigating Brain-Penetrant Selective WEE1 Inhibitor for Brain Cancer Patients
Debiopharm further explores the potential of its potent, highly selective WEE1 inhibitor Debio 0123 in phase 1 cancer study
Debiopharm to Present Late Breaking Head & Neck Cancer Abstract at the 2020 European Society Of Medical Oncology Congress
Debiopharm Advances into the Highly Anticipated Clinical Phase for their Potent WEE1 Inhibitor